Representatives from insulinmanufacturers blamed a system that requires them to pay higher andhigher rebates to pharmacy-benefit managers to gain access to thepatients whose prescriptions the PBMs manage.

Decisions by two of the world's biggest insulin producers to offer bigger discounts ondrugs used by millions of diabetics are raising questions fromCongress about whether the companies could have done so sooner.

On Wednesday, French drugmaker Sanofi said it would increasediscounts on insulin for some patients. The move follows recentefforts by Cigna Corp., which runs a major drug plan, and Eli Lilly& Co., another major insulin producer, to lower patients'out-of-pocket costs for the drugs.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.